PL2256500T3 - Zastosowanie inhibitorów enzymu TKTL1 - Google Patents

Zastosowanie inhibitorów enzymu TKTL1

Info

Publication number
PL2256500T3
PL2256500T3 PL10009323T PL10009323T PL2256500T3 PL 2256500 T3 PL2256500 T3 PL 2256500T3 PL 10009323 T PL10009323 T PL 10009323T PL 10009323 T PL10009323 T PL 10009323T PL 2256500 T3 PL2256500 T3 PL 2256500T3
Authority
PL
Poland
Prior art keywords
agf
mam
individual
patient
tktl1
Prior art date
Application number
PL10009323T
Other languages
English (en)
Inventor
Johannes F Coy
Original Assignee
Coy Dr Johannes F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05004930A external-priority patent/EP1701165A1/en
Application filed by Coy Dr Johannes F filed Critical Coy Dr Johannes F
Publication of PL2256500T3 publication Critical patent/PL2256500T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
PL10009323T 2005-03-07 2006-03-03 Zastosowanie inhibitorów enzymu TKTL1 PL2256500T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05004930A EP1701165A1 (en) 2005-03-07 2005-03-07 Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
EP05013170 2005-06-17
EP10009323.6A EP2256500B1 (en) 2005-03-07 2006-03-03 Use of inhibitors of the enzyme TKTL1.
EP06723195A EP1856537B1 (en) 2005-03-07 2006-03-03 Method for checking and controlling the mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism

Publications (1)

Publication Number Publication Date
PL2256500T3 true PL2256500T3 (pl) 2014-10-31

Family

ID=36224891

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10009323T PL2256500T3 (pl) 2005-03-07 2006-03-03 Zastosowanie inhibitorów enzymu TKTL1
PL06723195T PL1856537T3 (pl) 2005-03-07 2006-03-03 Sposób sprawdzania i kontroli procesu fermentacji kwasu mlekowego u ssaków/ścieżki metabolicznej tlenowej fermentacji glukozy w organizmie ssaczym

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06723195T PL1856537T3 (pl) 2005-03-07 2006-03-03 Sposób sprawdzania i kontroli procesu fermentacji kwasu mlekowego u ssaków/ścieżki metabolicznej tlenowej fermentacji glukozy w organizmie ssaczym

Country Status (11)

Country Link
US (3) US7754437B2 (pl)
EP (2) EP2256500B1 (pl)
JP (1) JP5095600B2 (pl)
AT (1) ATE509279T1 (pl)
AU (1) AU2006222277B2 (pl)
CA (1) CA2600206C (pl)
DK (2) DK1856537T3 (pl)
ES (1) ES2480416T3 (pl)
PL (2) PL2256500T3 (pl)
PT (1) PT2256500E (pl)
WO (1) WO2006094716A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007013903A1 (de) 2007-03-20 2008-09-25 Coy, Johannes F., Dr. Getränk
DE102010007243B4 (de) * 2010-02-09 2011-11-17 Frank Kischkel Therapieoptimierung bei Krebspatienten durch Austesten von Therapiekombinationen mittels in vitro Testungen (Zusatz)
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
DE102020116980A1 (de) * 2020-06-27 2021-12-30 TAVARGENIX GmbH Verwendung von Co-Enzym-Antagonisten zur Stoffwechselverlangsamung
CN112730734A (zh) * 2020-12-22 2021-04-30 河南星汉生物科技有限公司 一种葡萄糖发酵乳酸中发酵液残糖的检验方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006219A (en) * 1972-08-10 1977-02-01 Ceres Pharmacal Company Composition and method for countering effects of alcohol consumption
DE2834706A1 (de) * 1978-08-08 1980-02-14 Boehringer Mannheim Gmbh Verfahren und reagens zur bestimmung von glutamat-oxalacetat-transaminase und glutamat-pyruvat-transaminase
US4594237A (en) * 1984-04-16 1986-06-10 Walter Ziegler Method for testing chemical and biological substances
US6919185B2 (en) * 2000-05-31 2005-07-19 Bayer Aktiengesellschaft Regulation of human transketolase-like enzyme
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
EP1354961B1 (en) 2002-04-19 2008-01-23 Johannes Dr. Coy Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene

Also Published As

Publication number Publication date
CA2600206A1 (en) 2006-09-14
PT2256500E (pt) 2014-07-18
JP2008531065A (ja) 2008-08-14
DK2256500T3 (da) 2014-07-14
AU2006222277B2 (en) 2011-04-07
CA2600206C (en) 2011-01-04
PL1856537T3 (pl) 2011-10-31
US7754437B2 (en) 2010-07-13
DK1856537T3 (da) 2011-07-18
ATE509279T1 (de) 2011-05-15
US20080095703A1 (en) 2008-04-24
EP1856537A1 (en) 2007-11-21
US20100240687A1 (en) 2010-09-23
US11236381B2 (en) 2022-02-01
AU2006222277A1 (en) 2006-09-14
US11359225B2 (en) 2022-06-14
EP2256500A2 (en) 2010-12-01
ES2480416T3 (es) 2014-07-28
JP5095600B2 (ja) 2012-12-12
EP2256500B1 (en) 2014-04-23
US20200248227A1 (en) 2020-08-06
WO2006094716A1 (en) 2006-09-14
EP1856537B1 (en) 2011-05-11
EP2256500A3 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
Rajan et al. Monitoring pH, temperature and humidity in long-term stem cell culture in CO 2 incubator
Scheper et al. Bioanalytics: detailed insight into bioprocesses
WO2008133729A3 (en) Sequential analysis of biological samples with intermediate bleaching of fluorescence detector
Dietzsch et al. On-line multiple component analysis for efficient quantitative bioprocess development
Armiger et al. The interpretation of on-line process measurements of intracellular NADH in fermentation processes
CN103698541B (zh) 谷氨酸发酵在线检测系统及采用该系统在线检测的方法
Lladó Maldonado et al. A fully online sensor‐equipped, disposable multiphase microbioreactor as a screening platform for biotechnological applications
WO2017153992A1 (en) Method and system for continuous biosensing
WO2008064067A3 (en) Method for the sequential analysis of different components in a single biological sample and reagents therefor
DE50000413D1 (de) Verfahren, gefäss und vorrichtung zur überwachung der stoffwechselaktivität von zellkulturen in flüssigen medien
DE69922965D1 (de) Luftleerer sensor zum nachweis von mikroorganismen in blutproben und entsprechende methode
BRPI0507376A (pt) espécie oxidável como uma referência interna para biossensores e método de uso
WO2018052834A1 (en) Self regulating bioreactor apparatus and methods
PT2256500E (pt) Utilização de inibidores da enzima tktl1
CN103528915A (zh) 智能型压感式bod测定仪
CN201935910U (zh) 一种检测水质毒性的装置
JPWO2016147313A1 (ja) 薬剤感受性試験装置及び薬剤感受性試験キット並びに薬剤感受性試験方法
Lamboursain et al. A lab‐built respirometer for plant and animal cell culture
US20240318121A1 (en) Method and apparatus for sterile and noninvasive measurements of substances in bioreactors and other sterile environments
Reddy et al. Studies on stress-susceptibility: the relationship between serum enzyme changes and the degree of stress-susceptibility
Håkanson et al. General sampling system for sterile monitoring of biological processes
CN100537777C (zh) 一种动物可食性组织中磺胺类药物残留筛选方法及其试剂盒
CN223620389U (zh) 用于检测水中微生物浓度的96孔定量盘
CN203479655U (zh) 智能型压感式bod测定仪
ATE455867T1 (de) Echtzeit-pcr unter zusatz von pyrophosphatase